Peptide Policy Watch https://peptidepolicywatch.com/ Plain-English explainers on peptides: what people are asking, the evidence, and the rules. en-us Sun, 25 Oct 2026 12:00:00 -0500 Where peptide regulation stands right now: a plain-English timelinehttps://peptidepolicywatch.com/2026/10/25/where-peptide-regulation-stands-timeline/https://peptidepolicywatch.com/2026/10/25/where-peptide-regulation-stands-timeline/Sun, 25 Oct 2026 12:00:00 -0500A plain-English timeline of peptide regulation as of October 25, 2026: what FDA documents show, what is only reported, and what is still pending. Peptides, in plain English: what they are, and why one word covers so muchhttps://peptidepolicywatch.com/2026/10/25/what-are-peptides-plain-english/https://peptidepolicywatch.com/2026/10/25/what-are-peptides-plain-english/Sun, 25 Oct 2026 12:00:00 -0500What peptides are, how FDA draws the line between a peptide and a protein, and why the same word covers approved medicines and wellness-market products. This week in peptide policy: October 19–25, 2026https://peptidepolicywatch.com/2026/10/25/weekly-quiet-week-interim-policy-pending/https://peptidepolicywatch.com/2026/10/25/weekly-quiet-week-interim-policy-pending/Sun, 25 Oct 2026 12:00:00 -0500A quiet week for official peptide and compounding actions, October 19-25, 2026, with the reported HHS interim policy still under White House review. Hims & Hers, the FTC and the FDA: who has actually said what about telehealth and compounded drugshttps://peptidepolicywatch.com/2026/10/25/telehealth-compounded-drugs-ftc-fda/https://peptidepolicywatch.com/2026/10/25/telehealth-compounded-drugs-ftc-fda/Sun, 25 Oct 2026 12:00:00 -0500What the FTC and FDA have each said about telehealth companies and compounded drugs, from public documents, and what each does not cover. Everyone in the gym is talking about peptides. Here's what the research actually sayshttps://peptidepolicywatch.com/2026/10/25/peptides-evidence-ladder-what-research-shows/https://peptidepolicywatch.com/2026/10/25/peptides-evidence-ladder-what-research-shows/Sun, 25 Oct 2026 12:00:00 -0500A plain-English evidence ladder, from cells to animals to people, applied to BPC-157: one 2025 review counted 1 human study, a 2026 review counts 3. Which popular gym peptides are banned in sport? What WADA's 2026 and 2027 lists namehttps://peptidepolicywatch.com/2026/10/25/peptides-athletes-wada-prohibited-list/https://peptidepolicywatch.com/2026/10/25/peptides-athletes-wada-prohibited-list/Sun, 25 Oct 2026 12:00:00 -0500Which peptides do WADA's 2026 and 2027 Prohibited Lists name, what strict liability means for supplements, and what WADA says about GLP-1 drugs. From insulin to Ozempic: a timeline of how peptide medicines went from niche to mainstreamhttps://peptidepolicywatch.com/2026/10/25/peptide-medicines-timeline-insulin-to-glp-1/https://peptidepolicywatch.com/2026/10/25/peptide-medicines-timeline-insulin-to-glp-1/Sun, 25 Oct 2026 12:00:00 -0500A dated timeline of how peptide medicines went from insulin to GLP-1 drugs, and how that changed the money, the FDA rules and public interest. The glutathione injection recall: what FDA's October 1 notice says, and what it doesn'thttps://peptidepolicywatch.com/2026/10/25/greenwich-rx-glutathione-recall-what-fda-published/https://peptidepolicywatch.com/2026/10/25/greenwich-rx-glutathione-recall-what-fda-published/Sun, 25 Oct 2026 12:00:00 -0500FDA's Oct 1, 2026 notice on a compounded glutathione injection recall for possible endotoxin: what it says, what CDC and FDA add, what's unconfirmed. GHK-Cu is in skincare and on FDA's compounding list. Here's what "except injectable" meanshttps://peptidepolicywatch.com/2026/10/25/ghk-cu-copper-peptide-skincare-fda-compounding/https://peptidepolicywatch.com/2026/10/25/ghk-cu-copper-peptide-skincare-fda-compounding/Sun, 25 Oct 2026 12:00:00 -0500GHK-Cu, the copper peptide in skincare, is on FDA's Category 1 compounding list except for injectables, with an advisory meeting due by February 2027. What FDA's "Category 1" and "Category 2" actually mean (and what they don't)https://peptidepolicywatch.com/2026/10/25/fda-compounding-categories-explained/https://peptidepolicywatch.com/2026/10/25/fda-compounding-categories-explained/Sun, 25 Oct 2026 12:00:00 -0500What FDA's Category 1 and Category 2 labels for compounded bulk substances mean, and what they do not mean, using FDA's own documents. "It's a peptide": three very different things hiding behind one wordhttps://peptidepolicywatch.com/2026/10/25/approved-peptide-medicines-vs-wellness-peptides/https://peptidepolicywatch.com/2026/10/25/approved-peptide-medicines-vs-wellness-peptides/Sun, 25 Oct 2026 12:00:00 -0500Approved peptide medicines, compounded drugs and wellness-market peptides side by side: what FDA reviewed, what a label tells you, and what it does not.